Notizie Newsletter
Frontline Daratumumab Triplet Approved in EU for Transplant-Ineligible Myeloma
November 19, 2019 - The European Commission has approved the triplet regimen of daratumumab with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The approval, ...Leggi tutto
Pembrolizumab Regimens Approved in EU for Frontline PD-L1+ HNSCC
November 20, 2019 - The European Commission has approved pembrolizumab as a monotherapy or in combination with platinum and 5-FU chemotherapy for the frontline treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) and ...Leggi tutto
A first version of the Pan-European Indoor Radon Map
A hypothetical Pan-European Indoor Radon Map has been developed using summary statistics estimated from 1.2 million indoor radon samples. In this study we have used the arithmetic mean (AM) over grid cells of 10 km × 10 km to predict a mean indoor radon concentration ...Leggi tutto
Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product
November 15, 2019 - Biological products play an increasingly central role in modern medicine, offering treatments for many serious illnesses. Commonly referred to as biologics, these medicines are generally made from natural or living sources, like animal and plant cells, ...Leggi tutto